Jupiter Topco LLC Acquires Shares of 46,265 Sarepta Therapeutics, Inc. $SRPT

Jupiter Topco LLC bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 46,265 shares of the biotechnology company’s stock, valued at approximately $831,000.

A number of other institutional investors also recently modified their holdings of the stock. AQR Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 214.2% during the 1st quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock valued at $344,000 after acquiring an additional 3,671 shares in the last quarter. Great Lakes Advisors LLC acquired a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at $224,000. Guggenheim Capital LLC boosted its stake in shares of Sarepta Therapeutics by 33.5% during the 2nd quarter. Guggenheim Capital LLC now owns 45,790 shares of the biotechnology company’s stock worth $783,000 after acquiring an additional 11,497 shares in the last quarter. First Trust Advisors LP boosted its position in Sarepta Therapeutics by 59.2% during the second quarter. First Trust Advisors LP now owns 627,561 shares of the biotechnology company’s stock worth $10,731,000 after purchasing an additional 233,391 shares during the period. Finally, California Public Employees Retirement System lifted its stake in shares of Sarepta Therapeutics by 7.1% in the second quarter. California Public Employees Retirement System now owns 115,340 shares of the biotechnology company’s stock worth $1,972,000 after buying an additional 7,665 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $22.50 on Monday. The firm has a market capitalization of $2.38 billion, a P/E ratio of -7.76, a price-to-earnings-growth ratio of 0.32 and a beta of 0.27. Sarepta Therapeutics, Inc. has a 1 year low of $14.68 and a 1 year high of $25.32. The firm’s fifty day simple moving average is $18.26 and its 200 day simple moving average is $18.47. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.42. The firm had revenue of $401.25 million during the quarter, compared to the consensus estimate of $366.39 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The business’s revenue was down 34.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.02 EPS. As a group, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 3.52 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on SRPT shares. Piper Sandler lowered their target price on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research note on Thursday, July 9th. Weiss Ratings lowered shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a research report on Wednesday, August 19th. HC Wainwright restated a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research report on Thursday, July 9th. Finally, Zacks Research upgraded Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Nine analysts have rated the stock with a Buy rating, six have assigned a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $25.06.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.